Marwan Fakih: Updated RIN results in MSS chemo-refractory non-liver metastatic colorectal cancer
Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared a post on LinkedIn, about his recent paper published in European Journal of Cancer:
Authors: Annie Xiao, Xiaochen Li, Chongkai Wang, Jian Ye, Marwan Fakih.
“Happy to share our updated RIN results in MSS chemo-refractory non-liver metastatic colorectal cancer – median OS 27.5 months. We never gave up on immunotherapy in microsatellite stable CRC (and low TMB).
We have shown that site of metastatic disease matters and that some of the non-liver metastatic disease patients can have very profound and durable responses to RIN therapy.
Here we show that a large proportion of the non-liver metastatic disease patients derived clinical benefits for several years after starting RIN (regorafenib ipilimumab nivolumab) treatment.
3 patients are without any active metastatic disease more than 3.5 years from initiating treatment (more than 1.5 years without any therapy) and with negative MRD assays. In some patients with MSS CRC, we believe immunotherapy can be potentially curative.
Check our updated clinical data on our RIN study in European Journal of Cancer.”
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared this post, adding:
“Glad to be practicing in an era of immunotherapy.
Regorafenib, ipilimumab, and nivolumab were potentially curative in microsatellite-stable tumor.
6 patients had ongoing benefit, including 3 who remain cancer-free >18 months after treatment…”
More posts featuring Marwan Fakih and Pashtoon Kasi.
Marwan Fakih, MD, is the Associate Director for Clinical Sciences at City of Hope and the Medical Director of the Briskin Center for Clinical Research.
As a Professor with clinical expertise in colorectal and gastrointestinal cancers, Dr. Fakih focuses on drug development and biomarker research in colorectal cancer, as well as leading Phase I and developmental therapeutics studies.
Pashtoon Kasi is the Medical Director of GI Medical Oncology at City of Hope, Orange County. Previously, Dr. Kasi served as an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of Iowa, following positions as an Assistant Professor of Medicine and Oncology at both the University of Iowa and Mayo Clinic.
He also served as the Director of Colon Cancer Research and Director of Precision Medicine Research for Liquid Biopsies at Weill Cornell Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023